Regenerative medicine – time to cut through the hype
This article was originally published in Scrip
Executive Summary
Regenerative medicine is widely seen as playing a vital future role in difficult-to-treat conditions like diabetes, Parkinson's disease and stroke. But can it really deliver on its promise, or is it simply being hyped up to persuade investors to put money into what is a young and unpredictable area of research?
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.